“… Data are presented in CCRT + ACT arm/in control CCRT only arm if not stated otherwise. Abbreviations: OS, overall survival; HR, hazard ratio; CI, confidence interval; CCRT, concurrent chemoradiation; ACT, adjuvant (consolidation) chemotherapy; RT, radiotherapy; n.a., not available; CIS, cisplatin; GEM, gemcitabine; FU, fluorouracil; PAC, paclitaxel; CAR, carboplatin; A, AUC; MIT, mitomycin C. a Mexico, Argentina, India, Panama, Bosnia and Herzegovina, Peru, Thailand, Pakistan, Australia; b Australia, New Zealand, USA, Saudi Arabia, Canada, China, Singapore; c HR was calculated by Parmar [ 37 ] and Tierney [ 38 ] methods; d Minimization using Pocock and Simon algorithm [ 39 ], balancing disease stage (IIB vs. III-IVA), tumor diameter (<5 cm vs. ≥5 cm), study center (not clear, probably 9 that is one per country), radiation equipment (cobalt-60 vs. linear accelerator), age (<55 vs. ≥55 years); e Stratified for six study centers; f Stratified for tumor stage; g Mixed block with stratification for disease stage (IIV vs. III-IVA) and histopathology (squamous vs. adenocarcinoma or adenosquamous carcinoma); h Stratified for nodal status, participating site, FIGO stage, age, planned extended-field radiotherapy; i Mean instead of median; j Interquartile range instead of range; k Including IIIB and IVA; l Estimated from categories (≤4; 4.1–6; 6.1–8; ≥8.1) weighted by frequencies; m Including squamous cell, poorly differentiated and adeno/squamous carcinoma; n Para-aortic lymph nodes >1 cm were exclusion criteria, but 2.3% in ACT arm and 4.7% in CCRT alone arm had at least one; o Previous chemotherapy was not an exclusion criterion, but all patients had newly diagnosed cervical cancer, so the previous chemotherapy/radiotherapy were allowed only for other cancers; p However, not for cervical cancer; q Rounded down to the last full month. …”